107-43-7C[N+](C)(C)CC(=O)[O-]KWIUHFFTVRNATP-UHFFFAOYSA-NGlycine betaine is the amino acid betaine derived from glycine. It has a role as a fundamental metabolite. It is an amino-acid betaine and a glycine derivative. It is a conjugate base of a N,N,N-trimethylglycinium.
107-43-7DTXSID8022666CHEMBL1182、CHEMBL95889CHEBI:17750Cosmetic ingredients (Betaine) -> CIR (Cosmetic Ingredient Review)
Antistatic; Viscosity controlling
Soluble
Solubility (g/100 g solvent): methanol, 55; ethanol, 8.7. Sparingly soluble in ether.
Slightly soluble in chloroform
In water, 6.11X10+5 mg/L at 19 °C
Very soluble
Soluble (in ethanol)
FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
This chemical does not meet GHS hazard criteria for 90.4% (274 of 303) of all reports.
Not Classified
Aggregated GHS information provided per 303 reports by companies from 5 notifications to the ECHA C&L Inventory.
Chemical: Methanaminium, 1-carboxy-N,N,N-trimethyl-, hydroxide, innersalt
Regulation (EC) No 2015/2283 Article 10
Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt is listed on the EPA's Chemical Data Reporting (CDR) system. Manufacturers and importers of Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt are required to report information about their production and use of this chemical to the EPA under the Toxic Substances Control Act (TSCA). (40 eCFR Part 711)
REACH registered substance: Betaine (EC: 203-490-6)
Trimethylglycine: Does not have an individual approval but may be used under an appropriate group standard
No evidence of mutagenicity; [HSDB] Does not cross the placenta well in animal experiments; [REPROTOX] Not irritating to skin or eyes of rabbits; Not sensitizing in guinea pig maximization test; No evidence of mutagenicity; [IUCLID] May cause irritation; [Alfa Aesar MSDS]
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl betaine hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Betaine hydrochloride/
Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: betaine hydrochloride is included in digestive aid drug products. /Betaine hydrochloride/
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
Betaine decreases plasma homocysteine concentrations in homocystinuria cases caused by deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl). The decrease of homocysteine is estimated to be 20-30% of pre-treatment levels. Betaine supplementation in patients with homocystinuria also improves metabolic abnormalities in cerebrospinal fluid. Reports have shown that depending on the type of homocystinuria, the therapeutic effectiveness of betaine alone may be limited, insufficient to decrease total homocysteine levels and prevent clinical symptoms. In patients with homocystinuria due to cystathionine beta-synthase (CBS) deficiency, betaine should be used when serum total homocysteine levels remain high despite dietary therapy. Patients taking betaine for several years do not show evidence of tolerance. Also, betaine concentrations are not correlated with homocysteine concentrations. In patients with MTHFR deficiency and cbl defects, betaine may increase methionine and S-adenosyl methionine (SAM) plasma levels. Patients with CBS deficiency without a dietary restriction of methionine may accumulate excessive amounts of methionine. Clinical data shows that in patients with CBS deficiency, increased plasma methionine levels were associated with cerebral edema.
Homocystinuria is a hereditary disorder characterized by high levels of the amino acid homocysteine. This condition can be caused by deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl). CBS converts homocysteine to cystathionine, and a deficiency in this enzyme can lead to an accumulation of homocysteine. MTHFR is responsible for producing 5-methyltetrahydrofolate, a methyl donor that participates in the conversion of homocysteine back to methionine; therefore, an MTHFR deficiency can also lead to homocystinuria. Additionally, a defect in cobalamin (vitamin B12) cofactor metabolism can lead to homocystinuria, since a metabolite of cobalamin (methylcobalamin) promotes the conversion of homocysteine to methionine. Betaine transfers a methyl group via the enzyme betaine homocysteine methyl transferase (BHMT), converting homocysteine back into methionine and dimethylglycine (DMG). In patients with homocystinuria, betaine reduces homocysteine levels and improves health outcomes.
No reaction records under the current filter.
Loading…
301-305°C
Decomposes around 293 °C
Liquid; Dry Powder
Deliquescent solid; [Merck Index] Powder; [Alfa Aesar MSDS]
Free-flowing, white crystals; Savoury
SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
The aim of this study was to assess the pharmacokinetics of orally administered betaine and its acute effect on plasma total homocysteine (tHcy) concentrations. Healthy volunteers (n = 10; 3 men, 7 women) with normal body weight (mean + or - SD, 69.5 + or - 17.0 kg), 40.8 + or - 12.4 yr old, participated in the study. The betaine doses were 1, 3, and 6 g. The doses were mixed with 150 mL of orange juice and ingested after a 12-hr overnight fast by each volunteer according to a randomized double-blind crossover design. Blood samples were drawn for 24 hr and a 24-hr urine collection was performed. Orally administered betaine had an immediate and dose-dependent effect on serum betaine concentration. Single doses of 3 and 6 g lowered plasma tHcy concentrations (P = 0.019 and P < 0.001, respectively), unlike the 1-g dose. After the highest dose, the concentrations remained low during the 24 hr of monitoring. The change in plasma tHcy concentration was linearly associated with betaine dose (P = 0.006) and serum betaine concentration (R2 = 0.17, P = 0.025). The absorption and elimination of betaine were dose dependent. The urinary excretion of betaine seemed to increase with an increasing betaine dose, although a very small proportion of ingested betaine was excreted via urine. In conclusion, a single dose of orally administered betaine had an acute and dose-dependent effect on serum betaine concentration and resulted in lowered plasma tHcy concentrations within 2 hr in healthy subjects.
The prophylactic efficiency of taurine or betaine pretreatment for the prevention of peroxidative changes induced by lipopolysaccharide treatment in the rat liver was investigated ... Lipopolysaccharide (10 mg/kg intraperitoneally) was given to rats pretreated with taurine (1.5%, w/v) or betaine (1.5%, w/v) in drinking water for 4 weeks and plasma transaminase activities as well as hepatic malondialdehyde, diene conjugate (DC), glutathione, alpha-tocopherol and ascorbic acid levels, and superoxide dismutase (SOD) and glutathione peroxidase activities were determined ... Significant increases in plasma transaminase activities and hepatic malondialdehyde and DC levels and decreases in hepatic glutathione and alpha-tocopherol levels and SOD and glutathione peroxidase activities were observed 6 h after lipopolysaccharide treatment. This treatment did not alter ascorbic acid levels in the liver compared with controls. Taurine or betaine pretreatment in lipopolysaccharide-injected rats caused significant decreases in plasma transaminase activities and hepatic malondialdehyde and DC levels, and significant increases in glutathione and alpha-tocopherol (not betaine) levels without changing ascorbic acid levels and SOD and glutathione peroxidase activities in the liver ... /According to the authors/ taurine or betaine pretreatment was effective in the prevention of lipopolysaccharide-induced hepatotoxicity and prooxidant status.
Concomitant use of betaine and folic acid may be additive with regard to the possible lowering of serum homocysteine levels.
... Remethylation of homocysteine to methionine can occur through either the folate-dependent methionine synthase pathway or the betaine-dependent betaine-homocysteine methyltransferase pathway. The relevance of betaine as a determinant of fasting total homocysteine (tHcy) is not known, nor is it known how the 2 remethylation pathways are interrelated ... The objectives of the study were to examine the relation between plasma betaine concentration and fasting plasma tHcy concentrations and to assess the effect of folic acid supplementation on betaine concentrations in healthy subjects ... A double-blind randomized trial of 6 incremental daily doses of folic acid (50-800 ug/day) or placebo was carried out in 308 Dutch men and postmenopausal women (aged 50 to 75 yr). Fasted blood concentrations of tHcy, betaine, choline, dimethylglycine, and folate were measured at baseline and after 12 wk of vitamin supplementation ... Concentrations of tHcy were inversely related to the betaine concentration (r = -0.17, P < 0.01), and the association was independent of age, sex, and serum concentrations of folate, creatinine, and cobalamin. Folic acid supplementation increased betaine concentration in a dose-dependent manner (P for trend = 0.018); the maximum increase (15%) was obtained at daily doses of 400 to 800 ug/day ... /The authors condluded/ the plasma betaine concentration is a significant determinant of fasting tHcy concentrations in healthy humans. Folic acid supplementation increases the betaine concentration, which indicates that the 2 remethylation pathways are interrelated.
In small, open label trials of betaine therapy for homocystinuria as well as in small controlled trials of betaine in other conditions (Alzheimer disease, nonalcoholic steatohepatitis), serum enzyme elevations and clinically apparent liver injury were not reported. Indeed, in some studies, betaine has been associated with significant declines in preexisting serum enzyme elevations in a proportion of patients with nonalcoholic fatty liver disease.
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 3(SRC), determined from a water solubility of 611,000 mg/L at 19.3 °C(2) and a regression-derived equation(3), indicates that betaine is expected to have very high mobility in soil(SRC). The estimated pKa of betaine, an inner salt, is 2.38(4). Volatilization of betaine from moist soil surfaces is not expected to be an important fate process(SRC) because ionic compounds do not volatilize. Betaine is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 1.4X10-8 mm Hg(SRC), determined from a fragment constant method(5). No information on the aerobic biodegradation of betaine was located; however, the mineralization of alkyl betaine surfactants is considerable (>60% BODT reached in 28-day screening tests(6,7)) indicating that it is likely that betaine is also readily mineralized(SRC). Betaine is expected to biodegrade under anaerobic conditions as well based on data indicating that it is removed during anaerobic sewage treatment(8).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 3(SRC), determined from a water solubility of 611,000 mg/L at 19.3 °C(2) and a regression-derived equation(3), indicates that betaine is not expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 2.38(4) indicates betaine, will exist entirely as an inner salt at pH values of 5 to 9 and therefore volatilization from water surfaces will not occur as ionic compounds do not volatilize. According to a classification scheme(5), an estimated BCF of 0.3(SRC), from its water solubility(2) and a regression-derived equation(6), suggests the potential for bioconcentration in aquatic organisms is low(SRC). No information on the aerobic biodegradation of betaine was located; however, the mineralization of alkyl betaine surfactants is considerable (>60% BODT reached in 28-day screening tests(7,8)) indicating that it is likely that betaine is also readily mineralized(SRC). Betaine is expected to biodegrade under anaerobic conditions as well based on data indicating that it is removed during anaerobic sewage treatment(9).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), betaine, which has an estimated vapor pressure of 1.4X10-8 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase betaine may be removed from the air by wet or dry deposition(SRC). Betaine does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(3).
The betaine concentration of over 400 foods in the U.S. was measured. Concentrations ranged from 0.3 to 1.9 mg/100 g food for 26 dairy and egg products, 0.4 to 28.8 mg/100 g food for 16 spices, 0 to 1.8 mg/100 g food for 7 samples of fats and oils, 1.8 to 23.3 mg/100 g food for 16 samples of chicken and turkey, 2.1 to 10.4 mg/100 g for 18 sausage and luncheon meats, 0.5 to 1396.1 mg/100 g for 15 samples of breakfast cereals, 0.1 to 0.8 mg/100 g for 35 fruits, 0.2 to 4.2 mg/100 g food for 10 pork product samples, 0.1 to 808.6 mg/100 g food for 62 vegetable products with beets and spinach containing significantly more betaine than other vegetables, 0.3 to 11.2 mg/100 g food for 12 nut and seed products, 6.3 to 12.8 mg/100 g food for 15 beef products, 0.1 to 8.1 mg/100 g food for 12 beverages, 2.1 to 62.1 mg/100 g food for 11 finfish and shellfish products, 0.1 to 39.6 mg/100 g food for 21 legumes and legume products, 7.6 to 33.9 mg/100 g food for 4 lamb, veal and game samples, 0.4 to 244.1 mg/100 g food for 43 baked products, 0.1 to 6.1 mg/100 g food for 20 sugars and sweets products, 0.3 to 1506.8 for 13 samples of cereal grains and pasta products, 0.5 to 98.2 mg/100 g for 50 samples of fast foods, 0.1 to 21.6 mg/100 g for 10 snacks (pretzels were 295.1 mg/100 g food)(1).
The CIR Expert Panel concluded that the eleven alkyl betaines listed below are safe in the present practices of use and concentration in cosmetics, when formulated to be non-irritating...Betaine...
Safe for use in cosmetics, with qualifications
The Koc of betaine is estimated as 3(SRC), using a water solubility of 611,000 mg/L at 19.3 °C(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that betaine is expected to have very high mobility in soil. The estimated pKa of betaine, an inner salt, is 2.38(4).
AEROBIC: No data on the aerobic biodegradation of betaine was located however, amphoteric surfactants based on the betaine structure have been shown to be mineralized to a significant extent. For example, C12-C14 alkyl betaine surfactants were shown to be readily biodegradable in 28-day closed bottle screening tests reaching >60% of the theoretical oxygen demand over this period(1,2).
ANAEROBIC: Betaine was nearly completely degraded in two full-scale anaerobic treatment plants(1).
Drug Induced Liver Injury Rank (DILIrank 2.0)
Betaine
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl betaine hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Betaine hydrochloride/
Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses. A number of active ingredients have been present in OTC drug products for various uses, as described below. However, based on evidence currently available, there are inadequate data to establish general recognition of the safety and effectiveness of these ingredients for the specified uses: betaine hydrochloride is included in digestive aid drug products. /Betaine hydrochloride/
Betaine acts as metabolic intermediate in transmethylating processes (creatine and methionine synthesis).
Betaine acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with homocystinuria. This reduces toxic concentrations of homocysteine, usually to 20 to 30% or less of pretreatment concentrations.
Betaine or trimethylglycine is a quarternary ammonium compound that was first discovered in the juice of sugar beets (Beta vulgaris). Betaine is a metabolite of choline ... and is a substrate in one of the two recycling pathways that convert homocysteine to L-methionine. The other and principal recycling reaction is catalyzed by the enzyme methionine synthase and uses methylcobalamin as a cofactor and 5-methyltetrahydrofolate as a cosubstrate.
Betaine-homocysteine methyltransferase (BHMT) is a zinc metalloenzyme which catalyzes the transfer of a methyl group from betaine to homocysteine in the formation of methionine. BHMT is found in the liver and kidneys and may also exist in brain tissue. Betaine acts to lower homocysteine levels in some with primary hyperhomocysteinemia/homocystinuria via this enzyme.
In healthy volunteers (n=12) given 50 mg/kg of betaine, the elimination half-life was 14.38 h. In volunteers given 100 mg/kg/day of betaine for 5 days, the distribution half-life was significantly longer, suggesting that the transport and redistribution processes of betaine were saturated.
Betaine is catabolized mainly in the mitochondria of liver and kidney cells. The transmethylation of betaine via betaine homocysteine methyl transferase (BHMT) leads to the formation of dimethylglycine.
Betaine is absorbed from the small intestines into the enterocytes. It is released by the enterocytes into the portal circulation which carries it to the liver where there is significant first-pass extraction and first-pass metabolism of betaine. The principal metabolic reaction is the transfer of a methyl group from betaine to homocysteine via the enzyme betaine-homocysteine methyltransferase. The products of the reaction are L-methionine and dimethylglycine. Betaine hydrochloride is converted to betaine in the alkaline environment of the small intestine.
/Betaine/ is a metabolite of choline ...
3SCV180C9W
BETAINE
Mechanisms of Action [MoA] - Methylating Activity
Established Pharmacologic Class [EPC] - Methylating Agent
Betaine is a Methylating Agent. The mechanism of action of betaine is as a Methylating Activity.
BETAINE
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.
Endogenous factors or drugs that increase the transport and metabolism of LIPIDS including the synthesis of LIPOPROTEINS by the LIVER and their uptake by extrahepatic tissues.
Betaine is rapidly absorbed and distributed. In healthy volunteers (n=12) given 50 mg/kg of betaine, the Cmax, tmax and AUC0,∞ were 0.939 mmol/L, 0.90 h and 5.52 mmol⋅h/L, respectively. No significant changes in absorption kinetics were observed after repeated betaine administration (100 mg/kg/day for 5 days). The absolute bioavailability of betaine anhydrous has not been determined.
Betaine is mainly eliminated by metabolism. With a slow elimination rate and assuming 100% bioavailability, the renal clearance of betaine is negligible (5% of total body clearance).
Based on a study done on healthy volunteers (n=12) given 50 mg/kg of betaine, the volume of distribution was 1.3 L/kg.
Based on a study done on healthy volunteers (n=12) given 50 mg/kg of betaine, total oral plasma drug clearance was 0.084 L/h⋅kg.
Betaine is absorbed from the small intestines into the enterocytes. It is released by the enterocytes into the portal circulation which carries it to the liver where there is significant first-pass extraction and first-pass metabolism of betaine. The principal metabolic reaction is the transfer of a methyl group from betaine to homocysteine via the enzyme betaine-homocysteine methyltransferase. The products of the reaction are L-methionine and dimethylglycine. Betaine hydrochloride is converted to betaine in the alkaline environment of the small intestine.
It is not known whether betaine is distributed into breast milk. However, its metabolic precursor, choline, is found in human breast milk in high concentrations .
CIR ingredient: Betaine
Occurs naturally in plants and animals; Used in the treatment of homocystinuria; [Merck Index] Used in soldering and resin curing fluxes, in organic synthesis, and in fisheries (promotes fish survival and aids transfer of salmon and trout from freshwater to seawater); [HSDB]
Soldering [Category: Heat or Machine]
In soldering, resin curing fluxes, organic synthesis; in treatment of homocystinuria
Lipotropic drug
Gastric acidifier /Betaine hydrochloride/
Oral: For solution: 1 g/level scoopful Cystadane, (Orphan Medical)
Oral: 1 gram per 1.7 mL of powder (one scoopful) (Rx) (Cystadane).
Cystadane (betaine anhydrous for oral solution)
Betaine, in the form of a white, granular, hygroscopic powder referred to as anhydrous betaine ...
EPA Safer Chemical Functional Use Classes -> Processing Aids and Additives
Safer Chemical Classes -> Green half-circle - The chemical is expected to be of low concern
Flavoring Agents -> JECFA Flavorings Index
Flavouring Agent -> FLAVOURING_AGENT -> JECFA Functional Classes
Pharmaceuticals -> Animal Drugs -> Approved in Taiwan
Cosmetics -> Antistatic; Viscosity controlling
Printing Ink Manufacturing
Methanaminium, 1-carboxy-N,N,N-trimethyl-, inner salt: ACTIVE
Uses1. Adding betaine to the feed has protective effects on the vitamins contained in the feed, also makes feed be tolerable to high temperature and can subject to long-term storage, and thus greatly improving feed utilization rate as well as reducing the costs. Adding 0.05% betaine to the chicken feed can substitute 0.1% methionine; adding betaine to the bait have palatability effect on both fishes and shrimp, thus betaine can be used as the swelling agent of aquatic product in large amount. Adding betaine to the pig feed added betaine can increase the appetite of pigs and increase the rate of lean meat. 1kg Betaine is equivalent to 3.5kg of methionine. The ability to provide methyl of betaine is 1.2 times as strong as that of choline chloride, and 3.8 times as strong as that of methionine with a very significant feed efficiency. 2. It is used as betaine type amphoteric surfactants, also used as leveling agent of dye vat dyes. 3. It can be used as feed grade anhydrous betaine for being as a feed additive. It is a natural and efficient methyl donor which can partially substitute methionine and choline chloride, lower the feed costs, reduce back-fat of pig, and increase the rate lean meat and carcass quality. 4. It can be used for lowering blood pressure, anti-fatty liver and anti-aging. 5. It can be used as a feed additive for promoting animal growth and increased disease resistance.
DescriptionBetaine is a natural compound extracted from Beta vulgaris, widely present in both leaves and roots. Within plants, betaine is synthesised through a two-step oxidation of choline within chloroplasts. The first step converts choline into betaine aldehyde, a rate-limiting step catalysed by choline monooxygenase. The second step converts betaine aldehyde to betaine, catalysed by betaine aldehyde dehydrogenase [1]. It possesses certain pharmacological activities and may be employed to treat deficiencies or defects in specific enzymes leading to hyperhomocysteinemia in blood and urine. This medication facilitates the removal of excess homocysteine from the body.[1] TAKABE T, TANAKA Y, TAKABE T. CHAPTER 2:Betaine in Sugar Beet[C]. 2015: 0. DOI:10.1039/9781782628446-00009.
UsesBetaine is an active ingredient in toothpaste to control the symptoms of dryness of the mouth. It is used to treat homocystinuria, which is a defect in the major pathway of methionine biosynthesis. It is also used for boosting the immune system and for improving athletic performance. It is helpful to prevent noncancerous tumors in the colon (colorectal adenomas).
Usesbetaine is a surfactant, humectant, and excellent skin conditioner. It is also used to build product viscosity and as a foam booster. It is found mostly in skin cleansers, shampoos, and bath products.
General DescriptionBetaine also called trimethylglycine or N,N,N triethylammonium acetate, is an analog of glycine with three methyl groups. It is highly compatible with polymerase chain reaction (PCR) buffer mixture. Betaine is a PCR enhancing reagent that is widely used for improving the yield and specificity of PCR products, especially during the PCR amplification of targets rich in GC content or those that form secondary structures resulting in poor yield. Betaine facilitates DNA strand separation and manages the DNA melting temperature (Tm) difference between the GC and AT pairs in DNA. It stabilizes the ds DNA by equalizing the contribution of GC- and AT-base pairs. Betaine has been broadly used to optimize multiplex and ‘long and accurate′ polymerase chain reaction (LA-PCR). The addition of 1.0-1.7 M aqueous betaine to a PCR mixture has been reported to reduce the base pair composition dependence on DNA strand melting.
DefinitionChEBI: The amino acid betaine derived from glycine.